Landscape and prognostic values of lymphocytes in patients with hepatocellular carcinoma undergoing transarterial embolization

Author:

Zhao Rui-dong12,Liu Ding-jie12,Li Jia-wei3,Wang Yong1,Lin Jun-hao1,Zhang Yi-tian1,Li Yong1,Zhan Mei-xiao23,Yin Zhi-nan345,Lu Li-gong12,Liu Bing12

Affiliation:

1. Department of Interventional Medicine, Zhuhai People's Hospital (Zhuhai Hospital affiliated with Jinan University) , 79 Kangning Road, Zhuhai, Guangdong 519000 , P.R. China

2. Guangdong Provincial Key Laboratory of Tumor Interventional Diagnosis and Treatment, Department of Interventional Medicine, Zhuhai People's Hospital (Zhuhai Hospital affiliated with Jinan University) , 79 Kangning Road, Zhuhai, Guangdong 519000 , P.R. China

3. The Biomedical Translational Research Institute, Faculty of Medical Science, Jinan University , 601 Huangpu Avenue, Guangzhou, Guangdong 510632, P.R.   China

4. Guangzhou Purui Biotechnology Co., Ltd. , North Tianhe Road 894, Guangzhou, Guangdong 510620 , P.R. China

5. Zhuhai Institute of Translational Medicine, Zhuhai People's Hospital (Zhuhai Hospital Affiliated with Jinan University) , 4 Yuanshan Road, Zhuhai, Guangdong 519000 , P.R. China

Abstract

Abstract Transarterial embolization, the first-line treatment for hepatocellular carcinoma, does not always lead to promising outcomes in all patients. A better understanding of how the immune lymphocyte changes after transarterial embolization might be the key to improve the efficacy of transarterial embolization. However, there are few studies evaluating immune lymphocytes in transarterial embolization patients. Therefore, we aimed to evaluate the short- and long-term effects of transarterial embolization on lymphocyte subsets in patients with hepatocellular carcinoma to identify those that predict transarterial embolization prognosis. Peripheral blood samples were collected from 44 patients with hepatocellular carcinoma at the following time points: 1 d before the initial transarterial embolization, 3 d after the initial transarterial embolization, and 1 mo after the initial transarterial embolization and subjected to peripheral blood mononuclear cell isolation and flow cytometry. Dynamic changes in 75 lymphocyte subsets were recorded, and their absolute counts were calculated. Tumor assessments were made every 4 to 6 wk via computed tomography or magnetic resonance imaging. Our results revealed that almost all lymphocyte subsets fluctuated 3 d after transarterial embolization, but only Tfh and B cells decreased 1 mo after transarterial embolization. Univariate and multivariate Cox regression showed that high levels of Th2 and conventional killer Vδ2 cells were associated with longer progressive-free survival after transarterial embolization. Longer overall survival after transarterial embolization was associated with high levels of Th17 and viral infection–specific Vδ1 cells and low levels of immature natural killer cells. In conclusion, transarterial embolization has a dynamic influence on the status of lymphocytes. Accordingly, several lymphocyte subsets can be used as prognostic markers for transarterial embolization.

Funder

Natural Science Foundation of Guangdong Province

Publisher

Oxford University Press (OUP)

Reference27 articles.

1. Recent advances in systemic therapy for hepatocellular carcinoma;Zhang;Biomark Res,2022

2. Hepatocellular carcinoma;Forner;Lancet,2018

3. [Chinese clinical practice guidelines for transarterial chemoembolization of hepatocellular carcinoma];Clinical Guidelines Committee of Chinese Interventionalists, C;Zhonghua Nei Ke Za Zhi,2021

4. Switching to systemic therapy after locoregional treatment failure: definition and best timing;Ogasawara;Clin Mol Hepatol,2020

5. Resident immune cells of the liver in the tumor microenvironment;Lu;Front Oncol,2022

Cited by 1 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

1. CD4+ T cells in antitumor immunity;Trends in Cancer;2024-09

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3